Cancer Therapeutics: Functionalized Magnetic Nanoparticles for Targeted Drug Delivery for the Treatment of Cancer

dc.audience.educationlevelInvestigadores/Researchers
dc.audience.educationlevelEstudiantes/Students
dc.audience.educationlevelMaestros/Teachers
dc.audience.educationlevelOtros/Other
dc.contributor.advisorSharma, Ashutosh
dc.contributor.authorde la Fuente Jiménez, Juan Luis
dc.contributor.catalogeremimmayorquin
dc.contributor.committeememberZentella Dehesa, Alejandro
dc.contributor.committeememberTapia Ramírez, José
dc.contributor.committeememberVera Hernández, Arturo
dc.contributor.departmentSchool of Engineering and Sciences
dc.contributor.institutionCampus Querétaroes_MX
dc.contributor.mentorOza, Goldie
dc.date.accepted2023-11-29
dc.date.accessioned2025-04-26T02:06:56Z
dc.date.embargoenddate2025-12-31
dc.date.issued2023
dc.description.abstractBreast cancer (BC) has been a terrible disease in which women had suffer due to all the emotional, financial, familiar, and healthy issues it come with. Several subtypes of BC can be treated with different medicinal approaches like hormone therapy. However, the triple negative breast cancer (TNBC) subtype is the more lethal, deathly, and with the worst survival rate due to the absence of the progesterone and estrogen receptors (PR and ER, respectively) as well as the human epidermal growth factor receptor 2 (HER2). This deficiency of receptors in TNBC patients creates a gap with the medicinal treatments since the existing ones are focused on being applied on those receptors. Therefore, new treatments are needed for assisting TNBC patients. One possible solution is found in the power of nanoparticles (NPs), especially magnetic NPs (MNPs) which can help treat TNBC patients. In the present study, zinc ferrite (ZFO) and lanthanum ferrite (LFO) MNPs were synthetized via co-precipitation method and then characterized for knowing their properties and behaviors. Several techniques were utilized for knowing the size, shape, surface and optical properties, magnetic and electron properties, and aggregation and stability. Once the characterization was completed, different cytotoxic assays were employed for knowing the potential toxicity of ZFO and LFO MNPs towards breast cancer cell lines. The occupied cell lines were breast adenocarcinoma cell (MCF-7), triple negative breast cancer (MDA-MB-231) and normal cell lines (HEK-293). The different results exhibit the MDA-MB-231 cell line as more susceptible to die once’s treated with the MNPs. vii Moreover, once the first step was completed, ZFO MNPs were coated with gold for making a more stable MNPs and then covered with folic acid (FA) and chemotherapeutic drug doxorubicin (Dox). This procedure is intended to make an active targeting of the newly ZFO nanocomposite since the breast cancer cells have an overexpression of FA receptors. In addition, the nanocomposites are characterized for knowing if gold, FA, and Dox are attached to the ZFO MNPs. Then to know if this newly formed nanocomposite can deliver the Dox in the tumor area which has a specific pH, different experiments are completed. This will clear the idea if functionalized nanocomposites can travel towards the tumor area and deliver Dox into the cancerous cells achieving a higher mortality.es_MX
dc.description.degreeDoctorado en Biotencologíaes_MX
dc.format.mediumTexto
dc.identificator320101
dc.identifier.citationde la Fuente Jiménez, J.L. (2023). Cancer Therapeutics: Functionalized Magnetic Nanoparticles for Targeted Drug Delivery for the Treatment of Cancer. [Tesis doctorado]. Instituto Tecnológico y de Estudios Superiores de Monterrey. Recuperado de: https://hdl.handle.net/11285/703570
dc.identifier.cvu748421es_MX
dc.identifier.orcidhttps://orcid.org/0000-0002-6223-7930
dc.identifier.urihttps://hdl.handle.net/11285/703570
dc.language.isoenges_MX
dc.publisherInstituto Tecnológico y de Estudios Superiores de Monterreyes_MX
dc.relationInstituto Tecnológico de Estudios Superiores de Monterrey
dc.relationCONAHCYT
dc.relation.isFormatOfdraftes_MX
dc.rightsopenAccesses_MX
dc.rights.embargoreasonHay información que se utilizará en futuras publicaciones y no puede ser exhibida al público.es_MX
dc.rights.urihttp://creativecommons.org/licenses/by-nc-nd/4.0es_MX
dc.subject.classificationMEDICINA Y CIENCIAS DE LA SALUD::CIENCIAS MÉDICAS::CIENCIAS CLÍNICAS::ONCOLOGÍA
dc.subject.keywordZinc ferrite
dc.subject.keywordLanthanum ferrite
dc.subject.keywordGold
dc.subject.keywordDoxorubicin
dc.subject.keywordNanocomposite
dc.subject.keywordBreast cancer
dc.subject.keywordDrug targeted delivery
dc.subject.keywordTriple negative breast cancer
dc.subject.lcshMedicine
dc.titleCancer Therapeutics: Functionalized Magnetic Nanoparticles for Targeted Drug Delivery for the Treatment of Canceres_MX
dc.typeTesis Doctorado / doctoral Thesises_MX

Files

Original bundle

Now showing 1 - 3 of 3
Loading...
Thumbnail Image
Name:
delaFuenteJimenez_TesisDoctorado.pdf
Size:
19.74 MB
Format:
Adobe Portable Document Format
Description:
Tesis Doctorado
Loading...
Thumbnail Image
Name:
delaFuenteJimenez_CartaAutorizacion.pdf
Size:
1.83 MB
Format:
Adobe Portable Document Format
Description:
Carta Autorización
Loading...
Thumbnail Image
Name:
delaFuenteJimenez_FirmasActadeGrado.pdf
Size:
85.93 KB
Format:
Adobe Portable Document Format
Description:
Firmas Acta de Grado

License bundle

Now showing 1 - 1 of 1
Loading...
Thumbnail Image
Name:
license.txt
Size:
1.3 KB
Format:
Item-specific license agreed upon to submission
Description:
logo

El usuario tiene la obligación de utilizar los servicios y contenidos proporcionados por la Universidad, en particular, los impresos y recursos electrónicos, de conformidad con la legislación vigente y los principios de buena fe y en general usos aceptados, sin contravenir con su realización el orden público, especialmente, en el caso en que, para el adecuado desempeño de su actividad, necesita reproducir, distribuir, comunicar y/o poner a disposición, fragmentos de obras impresas o susceptibles de estar en formato analógico o digital, ya sea en soporte papel o electrónico. Ley 23/2006, de 7 de julio, por la que se modifica el texto revisado de la Ley de Propiedad Intelectual, aprobado

DSpace software copyright © 2002-2026

Licencia